Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Oct;70(4):751-758.
doi: 10.1161/HYPERTENSIONAHA.117.09788. Epub 2017 Jul 31.

Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial)

Affiliations
Free PMC article
Randomized Controlled Trial

Visit-to-Visit Office Blood Pressure Variability and Cardiovascular Outcomes in SPRINT (Systolic Blood Pressure Intervention Trial)

Tara I Chang et al. Hypertension. .
Free PMC article

Abstract

Studies of visit-to-visit office blood pressure (BP) variability (OBPV) as a predictor of cardiovascular events and death in high-risk patients treated to lower BP targets are lacking. We conducted a post hoc analysis of SPRINT (Systolic Blood Pressure Intervention Trial), a well-characterized cohort of participants randomized to intensive (<120 mm Hg) or standard (<140 mm Hg) systolic BP targets. We defined OBPV as the coefficient of variation of the systolic BP using measurements taken during the 3-,6-, 9-, and 12-month study visits. In our cohort of 7879 participants, older age, female sex, black race, current smoking, chronic kidney disease, and coronary disease were independent determinants of higher OBPV. Use of thiazide-type diuretics or dihydropyridine calcium channel blockers was associated with lower OBPV whereas angiotensin-converting enzyme inhibitors or angiotensin receptor blocker use was associated with higher OBPV. There was no difference in OBPV in participants randomized to standard or intensive treatment groups. We found that OBPV had no significant associations with the composite end point of fatal and nonfatal cardiovascular events (n=324 primary end points; adjusted hazard ratio, 1.20; 95% confidence interval, 0.85-1.69, highest versus lowest quintile) nor with heart failure or stroke. The highest quintile of OBPV (versus lowest) was associated with all-cause mortality (adjusted hazard ratio, 1.92; confidence interval, 1.22-3.03) although the association of OBPV overall with all-cause mortality was marginal (P=0.07). Our results suggest that clinicians should continue to focus on office BP control rather than on OBPV unless definitive benefits of reducing OBPV are shown in prospective trials.

Clinical trial registration: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01206062.

Keywords: angiotensin-converting enzyme inhibitors; blood pressure; heart failure; kidney diseases; mortality.

Conflict of interest statement

CONFLICTS OF INTEREST/DISCLOSURES

Figures

Figure 1:
Figure 1:
Determinants of visit-to-visit office blood pressure variability (OBPV) from multivariable-adjusted linear regression models. Abbreviations: ACEI = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; PVD = peripheral vascular disease; NSAID = non-steroidal anti-inflammatory drug; BMI = body mass index
Figure 2:
Figure 2:
Event rates per 1000 patient-years of A) the primary composite endpoint; B) heart failure; C) stroke; and D) all-cause mortality by quintile of visit-to-visit office blood pressure variability (OBPV).

Similar articles

See all similar articles

Cited by 6 articles

See all "Cited by" articles

Publication types

MeSH terms

Substances

Associated data

Feedback